RhumbLine Advisers’s Titan Pharmaceuticals TTNP Stock Holding History

RhumbLine Advisers’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6	Closed	-$69K	–	2959
2017 Q1	$69K	Buy	6 +2	+50%	+$28.1K	﹤0.01%	2804
2016 Q4	$60K	Hold	4	–	–	﹤0.01%	2820
2016 Q3	$80K	Hold	4	–	–	﹤0.01%	2830
2016 Q2	$72K	Buy	+4	New	+$85.2K	﹤0.01%	2944

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

RhumbLine Advisers's TTNP Position: Q2 2017 in Review

RhumbLine Advisers sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 6 shares — an estimated $69K sold.

RhumbLine Advisers first reported a position in TTNP in Q2 2016 and held it in 4 quarters. The position peaked at $80K in Q3 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

RhumbLine Advisers reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
RhumbLine Advisers sold 6 Titan Pharmaceuticals shares in Q2 2017, an estimated $69K.
RhumbLine Advisers first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 4 quarters.
RhumbLine Advisers's Titan Pharmaceuticals position peaked at $80K in Q3 2016.
35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.